Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A tetravalent bispecific antibody targeting both the pro-apoptotic death receptor tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2; death receptor 5; DR5) and cadherin-17 (CDH17), with potential pro-apoptotic and antineoplastic activities. Upon administration of anti-TRAILR2/CDH17 tetravalent bispecific antibody BI 905711, the antibody targets and binds to both TRAILR2 and CDH17, expressed on tumor cells. Receptor clustering and activation of TRAILR2 induces apoptosis in CDH17-positive cancer cells. Activation of TRAILR2 plays a key role in the induction of apoptosis. CDH17-dependent clustering of TRAILR2 allows BI 905711 to selectively induce apoptosis in CDH17-expressing tumor cells thereby increasing efficacy and decreasing liver toxicity. CDH17 is overexpressed in a variety of cancer cell types while its expression is restricted in normal liver tissue.

**Synonyms:** - BI 905711 - BI-905711 - BI905711 - Bi-specific Agent BI 905711 - CDH17-targeting TRAILR2 Agonist BI 905711